Conference Proceedings: (Truncated to 50)

  1. Singh, A., Jayanthan, A., Hoeksema, K., Chi, S., Dunn, S., Narendran, A. Analysis of Functional Kinomics of CNS AT/RT Cells as Determined by Susceptibility to Diverse Targeted Inhibitors and Drug Combinations. Society for Neuro-Oncology Annual Meeting, New Orleans, U.S.A. May, 2011.
  2. Anderson, R., Singh, G., Jayanthan, A., Narendran, A. Plasma Cytokine Profiling of Disseminated Infantile Myofibramatosis: Implications for Etiology and Targeted Therapeutics. International Society of Paediatric Oncology Annual Meeting, Boston, U.S.A. October, 2010.
  3. Jayanthan, A., Bernoux, D., Singh, A., Bose, P., Riabowol, K., Narendran, A. Multi-Tyrosine Kinase Inhibitors in Pre-Clinical Studies For CNS AT/RT: Evidence for Target Modulation and Synergy with Irinotecan. International Society of Paediatric Oncology Annual Meeting, Boston, U.S.A. October, 2010.
  4. Jayanthan, A., Narendran, A. Aurora kinase inhibition and cell survival in pediatric leukemia. Alberta Genome Instability and Aging Conference, Calgary, Canada. June, 2010.
  5. Narendran, A., Jayanthan, A., Singh, A., Incoronato, A., Desai, S., Whitlock, J. SJG-136 (NSC 694501), A unique DNA Minor Groove Interstrand Cross-Linking Agent Shows Significant Activity and Drug Combinability In Vitro Against Aggressive Types of Pediatric Leukemia. American Society of Pediatric Hematology/Oncology Annual Meeting, Montreal, Canada. April, 2010.
  6. McKenzie, B., Zemp, FJ., Lun, X., McFadden, G., Narendran, A., Forsyth P. Alberta Cancer Foundation Overcoming Resistance to Oncolytic Myxoma Virus in Brain Tumour Initiating Cells and Syngenic Glioma Models Meeting 2010.
  7. McKenzie, B., Zemp, FJ., Lun, X., McFadden, G., Narendran, A., Forsyth P. Getting in touch with their sensitive side: Using drug screen approaches to enhance sensitivity of Brain Tumour Stem Cells to Myxoma virus. 6th International Meeting on Oncolytic Viruses as Cancer Therapeutics 2011 *abstract ranked outstanding and selected for travel award.
  8. McKenzie, B., Zemp, FJ., Lun, X., McFadden, G., Narendran, A., Kurz, E., Forsyth P. Novel combination treatments enhance sensitivity of Brain Tumour Initiating Cells to oncolytic Myxoma virus therapy Society for Neuro-Oncology Annual Meeting New Orleans. May 19-20, 2011
  9. Banderali, U., Jayanthan, A., Belke, D., Giles, WR., Narendran,A. Potassium channels in the membranes of AML and ALL cells: Involvement in proliferation. Alberta Cancer Foundation research Meeting. Banff, November 8-10, 2010.
  10. Clarkson, M., McManus, A., Nishikawa, S., Narendran, A., Johnston R. Oncolytic Reovirus as a Novel Therapeutic for Pediatric Leukemia. Meeting: BMB Advance 2011 Banff Centre April 29th – 30th.
  11. Narendran, A., Jayanthan, A., Singh, A., Incoronato, A., Desai, S., Whitlock, J. SJG-136 (NSC 694501), A unique DNA Minor Groove Interstrand Cross-Linking Agent Shows Significant Activity and Drug Combinability In Vitro Against Aggressive Types of Pediatric Leukemia. American Society of Pediatric Hematology/Oncology Annual Meeting, April, 2010. Montreal, Canada.
  12. Lotfi, S., Jayanthan, A., Lewis, V.A., Guilcher, G., Squires, M.S., Cooper, T., Narendran, A. AT9283, a novel Aurora kinase/Jak2 inhibitor demonstrates activity against refractory infant leukemia cells: Studies on growth inhibition, biological correlates, drug synergy and effects on leukemia stem-like cells. American Society of Hematology Annual Meeting, December, 2009. New Orleans, U.S.A.
  13. Jayanthan, A., Lotfi, S., Cooper, T., Narendran, A. Targeting Aurora kinases in refractory infant leukemia: In vitro cytotoxicity, drug synergy and target modulation of the novel inhibitor AT9283. Alberta Cancer Research Institute Annual Meeting, November, 2009. Banff, Canada.
  14. Singh, A., Jayanthan, A., Narendran, A. A sequence-selective minor groove DNA binding agent induces cell death in pediatric leukemia cells at sub nanomolar concentrations: Preclinical studies of a potential novel targeted therapeutic agent. Alberta Cancer Research Institute Annual Meeting, November, 2009. Banff, Canada.
  15. Woldum, E., Jayanthan, A., Farran, A., Singh, A., Farran, P., Narendran, A. The opioid methadone inhibits the growth and survival of sarcoma cells and synergizes with the multikinase inhibitor sorafenib to induce potent anti-tumor activity. Alberta Cancer Research Institute Annual Meeting, November, 2009. Banff, Canada.
  16. Banderali, U., Jayanthan, A., Kondo, C., Narendran, A., Giles, W. Ion channels as new potential targets in cancer therapy. Alberta Cancer Research Institute Annual Meeting, November, 2009. Banff, Canada.
  17. Jayanthan, A., Howard, S.C., Trippett, T., Horton, T.M., Daisley, L., Lewis, V.A., Narendran, A. Targeting the Bcl-2 family of proteins in Hodgkin Lymphoma: In vitro cytotoxicity, target modulation and drug combination studies of the BH3 mimetic ABT-737. American Society of Hematology Annual Meeting, December, 2008, San Francisco, U.S.A.
  18. D Bernoux, M Blough, J Kelly, Cairncoross, A Narendran. The effect of heat shock protein inhibition in brain tumor stem cells. Society for Neuro-Oncology, 13th Annual Meeting. Las Vegas. Nov 20, 2008.
  19. D Bernoux, A Narendran. Pre-clinical studies for the identification of novel therapeutic agents for the treatment of CNS AT/RT tumors in children. European Pediatric Conference, Nice, France. Oct 20, 2008.
  20. Narendran A, Gore L, Bagatell R, Whitlock J, Kersey, Boklan J, Katzenstein H, Hunger S, Amid A, Booth K, Herzog C, Arceci R and Trippett T. An Experimental Model for Target Modulation Analysis in Early Clinical Trials: Effects on Hsp90 Client Proteins in Cells of Patients Treated with 17-AAG. American Society for Pediatric Hematology and Oncology Annual Meeting Toronto, May, 2007.
  21. Jayanthan A, Incornato A, Fowler J, Anderson R, Whitlock J and Narendran A. Pre-Clinical Studies on the Novel Chemotherapeutic Agent SJG-136 for the Treatment of Refractory Acute Lymphoblastic Leukemia in Children. American Society for Pediatric Hematology and Oncology Annual Meeting Toronto May, 2007.
  22. Miettunen P, Jayanthan A and Narendran A. Soluble IL-2 receptor, a marker for T-lymphocyte activation, is inconsistently elevated in pediatric patients with macrophage activation syndrome. Arthritis & Rheumatism, 2006, September; 54 (9).
  23. Narendran A, Ujack E, Jayanthan A, Pihl K, Lamers S, Lewis V, Desai S, Brown C and Coppes M. Molecular Characterization of GM-CSF Receptor Hypersensitivity in Juvenile Myelomonocytic Leukemia (JMML) by siRNA Studies. International Society for pediatric oncology annual meeting September 2006.
  24. Miettunen PM, Lewis V, Le D and Narendran A. Effective treatment of infantile onset macrophage activation syndrome/hemophagocytic lymphohistiocytosis (MAS/HLH) with etanercept. Journal of Rheumatology, 2006, February; 33 (2).
  25. Miettunen PM, Ding Y and Narendran A. Cytokine profiles of serum proteomic patterns in the sera of pediatric patients with macrophage activation syndrome (MAS): Implications for rapid diagnosis. Journal of Rheumatology, 2006, February; 33 (2).
  26. Miettunen PM, Ding Y and Narendran A. Cytokine profiles of serum proteomic patterns in the sera of pediatric patients with macrophage activation syndrome (MAS): Implications for rapid diagnosis. Clinical Immunology, 2006, 119 (S).
  27. Jayanthan A, Lamers F, Fowler J, Hawkins L, Ujack E and Narendran A. Studies on the Effectiveness and Biological Correlative Analysis of 17-DMAG on Neuroblastoma (NB) Cells. Advances in Neuroblastoma Research, International meeting, Los Angeles, 2006.
  28. Jayanthan A, Incoronato A, Booth K, Anderson R and Narendran A. Pre-clinical Studies on the Novel Chemotherapeutic Agent SJG-136 for the Treatment of Infant Acute Lymphoblastic Leukemia. Alberta Cancer Board Annual Meeting Banff, 2006.
  29. K Koro, E French, C Egan, A Narendran, F Green, A Magliocco. Investigating the Role of Osteopontin in the Metastasis of Breast Cancer to Bone using an in vitro Cell Co-culture model system. Alberta Cancer Board Annual Meeting, Banff, Alberta. 2006.
  30. Ujack E, Blackmore C, Shin B, Magliocco T, Coppes M and Narendran A. Molecular Histological Characterization of Wilms' Tumour Using Dissociable Antibody Arrays. International Society for Pediatric oncology Annual meeting, Vancouver, BC September 19-25, 2005 Pediatric Blood and Cancer.
  31. Jayanthan A, Fowler J, Ding Y MD and Narendran A MD, PhD. In vitro activity, synergism and molecular changes induced by oxaliplatin in pediatric ALL cells. International Society for Pediatric oncology Annual meeting, Vancouver, BC September 19-25, 2005.
  32. Connor AM, Narendran A, Bogoch E andKeystone EC. Lovastatin Induces Apoptosis of Fibroblast-Like Synoviocytes. October 16-21, 2004 American College of RheumatologyACR/ARHP 68th Annual Scientific Meeting October 16-21, 2004 in San Antonio, Texas.
  33. Connor AM, Narendran A, Bogoch E and Keystone EC. Tumor necrosis factor alpha modulates fibroblast-like synoviocyte expression of lymphangiogenesis-associated vascular endothelial growth factor. C Connor AM, Narendran A, Bogoch E and Keystone EC Global Arthritis Research Network (GARN): 4th World Congress on Arthritis in Montreal, Quebec, Canada, 20–22 September 2004, Global Arthritis Research Network (GARN): 4th World Congress on Arthrit.
  34. Burgess G, Hawkins L and Narendran A. HER-2/NEU Receptor tyrosine kinase and its putative ligand in pediatric ALL: Evidence for multiple cell signaling pathways. 36th Congress of the International Congress of the International Society of Pediatric Oncology Oslo , 2004.
  35. Hawkins LM and Narendran A. Studies Using 17-Allylamino-17-demethoxygeldanamycin (17-AAG) to understand the Heterogeneity of Hsp90 Linked Survival and Signalling Pathways in Neuroblastoma Advances in Neuroblastoma Research. 2004 Eleventh Congress Genoa, Italy, 2004.
  36. Connor AM, Narendran A, Bogoch E and Keystone EC. Tumor necrosis factor alpha modulates fibroblast-like synoviocyte expression of lymphangiogenesis-associated vascular endothelial growth factor C. Arthritis Res Ther 2004 6:99.
  37. Narendran A, Tijan B, Coppes L, Rhemtullah F and Anderson R. In Vitro Growth Stimulation and the Identification of Potential Signaling Pathways in t (4; 11), Pediatric Pre-B Acute Lymphoblastic Leukemia. (ALL) American Society for Hematology, Annual Meeting San Diego 2004.
  38. Burgess G, Hawkins L and Narendran A. HER-2/NEU in pediatric ALL. Alberta Cancer Board Annual Meeting Banff, 2004.
  39. Jayanthan AA, Hawkins LM and Narendran A. Effects of Geldanamycin on Imatinib Mesylate Sensitive and Resistant Ph+ Pediatric Acute Lymphoblastic Leukemia. ASH Annual Meeting, December 6-9 2003 Blood 102:11 2003.
  40. Hawkins LM, Jayanthan AA and Narendran A. The Effects of Alendronate on Bone Marrow Stromal Cell Physiology: Implications for Acute Lymphoblastic Leukemia (ALL) Cell Growth, Survival and Chemosensitivity. ASH Annual Meeting, December 6-9 2003 Blood 102:11 2003.
  41. Burgess G, Hawkins LM, Timm-McCann M, Magliocco A and Narendran A. Her2/Neu in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. ACB Annual Meeting, November 12-14 2003.
  42. Hawkins L, Burgess G, Jayanthan AA and Narendran A. The Induction of Apoptosis is Acute Lymophoblastic Leukemia by 17-allylamino-17-demethoxygeldanamycin. ACB Annual Meeting, November 12-14 2003.
  43. Kim A, Hawkins L, Thirukkumaran C, Luider J, Narendran A and Morris D. Induction of Reovirus Mediated Apoptosis in Myelomonocytic Leukemia (JMML) Cells: A Novel Therapeutic Approach. ACB Annual Meeting, November 12-14 2003.
  44. Narendran A, Hawkins LM, Vanek W, Jayanthan AA and Freedman MH. Induction of Apoptosis in Juvenile Myelomonocytic Leukemia (JMML) Cells by Geldanamycin. ASH Annual Meeting, December 6-9 2003 Blood 102:11 2003.
  45. Narendran A, Weitzner B and Freedman MH. STI571 Prevents bFGFR and VEGFR1 Autophosphorylation and Induces Apoptosis in Bone Marrow Stromal Cells. Annual Meeting of the American Society of Hematology (ASH), December 2002.
  46. Narendran A and Freedman MH. Influence of genetic alterations in bone marrow stromal cells on leukemic cell growth Hematological malignancies and the marrow microenvironment workshop. Invited presentation National Institutes of Health, National Cancer Institute Bethesda, Maryland September 23, 2002.
  47. Narendran A, Ganjavi H, Connor A, Keystone E, Malkin D and Freedman MH. The p53 mutations in bone marrow stromal cells may play a critical role in leukemia through the induction of angiogenic and lymphangiogenic factors. Proceedings of the American Association for Cancer research 2002, 43:1053.
  48. Barlow JW, Mous M, Narendran A, Gee M, Freedman MH and Malkin D. Retinoic acid as a differentiation therapy for rhabdomyosarcoma cell lines. Proceedings of the American Association for Cancer research 2002, 43:432.
  49. Narendran A, Ganjavi H, Barlow J, Malkin D and Freedman MH. The p53 status in bone marrow stromal cells influences production of pro-angiogenic factors and growth of acute lymphoblastic leukemia. Blood (Abstract) 2001 (11) 1373.
  50. Narendran A and Freedman MH. Pro-angiogenic cytokine pathways in acute lymphoblastic leukemia. Presented at the 42nd Annual Meeting of the American Society of Hematology (ASH), December 2000.